Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

Pharmacogenetics and Genomics

Volumn 23, Issue 10, 2013, Pages 549-557

  De Mattia, Elena ^a   Toffoli, Giuseppe ^a   Polesel, Jerry ^a   D'Andrea, Mario ^b   Corona, Giuseppe ^a   Zagonel, Vittorina ^c   Buonadonna, Angela ^a   Dreussi, Eva ^a   Cecchin, Erika ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

ABC SLC transporter genetic markers; colorectal cancer; FOLFIRI; genotype phenotype association; irinotecan; pharmacogenomics; pharmacokinetics; response; survival; UGT1As genetic markers

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; SOLUTE CARRIER PROTEIN; UNCLASSIFIED DRUG;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; GENETIC VARIATION; GENOTYPE; HUMANS; LEUCOVORIN; LINKAGE DISEQUILIBRIUM; NEOPLASM METASTASIS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84885084652     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328364b6cf     Document Type: Article

References (50)

1. Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010; 596:95-121.
2. Huang Y, Penchala S, Pham AN, Wang J. Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin Drug Metab Toxicol 2008; 4:237-254.
3. Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD. Transporter pharmacogenetics: Transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med 2012; 13:19-34.
4. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett 2006; 239: 168-182.
5. Ross DD, Nakanishi T. Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol 2010; 596:251-290.
6. Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ ABCP/ABCG2). Handb Exp Pharmacol 2011; 201:325-371.
7. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11:155-166.
8. Paolo AD, Bocci G, Polillo M, Re MD, Desidero TD, Lastella M, Danesi R. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 2011; 12:932-943.
9. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1.*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061-3068.
10. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:866-871.
11. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1.*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 2007; 99:1290-1295.
12. Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: A predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009; 20:867-879.
13. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28:4697-4705.
14. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570-3577.
15. ChuaW, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 2011; 79:224-250.
16. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9:489-499.
17. Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, et al. Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Crit Rev Oncol Hematol 2013; 85:121-135.
18. Srinivasan BS, Chen J, Cheng C, Conti D, Duan S, Fridley BL, et al. Methods for analysis in pharmacogenomics: Lessons from the Pharmacogenetics Research Network Analysis Group. Pharmacogenomics 2009; 10:243-251.
19. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27:2457-2465.
20. Dias MM, McKinnon RA, Sorich MJ. Impact of the UGT1A1.*28 allele on response to irinotecan: A systematic review and meta-analysis. Pharmacogenomics 2012; 13:889-899.
21. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8:278-288.
22. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5- fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31:2137-2142.
23. Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 2010; 11:391-406.
24. Akiyama Y, Fujita KI, Ishida H, Sunakawa Y, Yamashita K, Kawara K, et al. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet 2012; 27:325-335.
25. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11:61-71.
26. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
27. Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 2011; 11:214-226.
28. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-440.
29. Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, et al. Pharmacogenetics of SLCO1B1 gene and the impact of .*1b and .*15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006; 16:683-691.
30. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604-2614.
31. Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006; 97:192-198.
32. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280:1216-1223.
33. Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P, Schuetz E. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 2008; 36:780-795.
34. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecantreated metastases. Int J Cancer 2004; 109:848-854.
35. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003; 9:3052-3057.
36. Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006; 343:571-577.
37. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007; 26:183-201.
38. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 1994; 54:3723-3725.
39. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56:3752-3757.
40. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008; 59:69-75.
41. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33:434-439.
42. Iwatani Y, Shimada Y, Seima Y, Yamazaki T, Miyazaki N. The biological and clinicopathological characteristics of right-sided colon cancer. Oncol Rep 2000; 7:991-994.
43. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 2008; 23:418-423.
44. Chu XY, Kato Y, Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab Dispos 1999; 27:440-441.
45. Iyer L, Ramirez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 2002; 49:336-341.
46. Luo FR, Paranjpe PV, Guo A, Rubin E, Sinko P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 2002; 30:763-770.
47. Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets 2011; 12:631-646.
48. Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42 (Suppl): S44-S49.
49. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Salagacka A, Mirowski M. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 2010; 25:1167-1176.
50. He T, Mo A, Zhang K, Liu L. ABCB1/MDR1 polymorphism and colorectal cancer risk: A meta-analysis of case-control studies. Colorectal Dis 2013; 15:12-18.